Heart Failure Duration Combined with Left Atrial Dimension Predicts Super-Response and Long-Term Prognosis in Patients with Cardiac Resynchronization Therapy Implantation
Table 2
Univariate and multivariate logistic regression analyses of predictors of super-response.
Univariate analysis
Multivariate analysis
Baseline characteristics
OR (95% CI)
P Value
OR (95% CI)
P Value
Age
1.02 (0.96-1.07)
0.616
Gender
2.10 (0.67-6.56)
0.202
NYHA class
0.61 (0.25-1.49)
0.274
HF duration
0.97 (0.94-0.99)
0.003
0.95 (0.92-0.98)
0.002
Hypertension
1.71 (0.50-5.86)
0.397
Diabetes
2.19 (0.47-10.29)
0.322
Atrial fibrillation
0.38 (0.04-3.23)
0.372
Ischemic etiology
1.85 (0.48-7.10)
0.373
LVEF
1.10 (0.96-1.26)
0.186
LAD
0.83 (0.74-0.94)
0.003
0.72 (0.58-0.89)
0.002
LVEDD
0.96 (0.89-1.03)
0.246
MR
0.88 (0.75-1.02)
0.081
1.21 (0.89-1.65)
0.223
QRS duration
1.02 (1.00-1.05)
0.115
LBBB
6.05 (1.26-28.98)
0.024
10.91 (1.30-91.64)
0.028
ACE-I/ARB
1.57 (0.17-14.43)
0.691
Beta-blockers
1.92 (0.22-17.17)
0.559
Spironolactone
1.63 (0.32-8.29)
0.556
NYHA: New York Heart Association; HF: heart failure; LVEF: left ventricular ejection fraction; LAD: left atrial dimension; LVEDD: left ventricular end-diastolic dimension; MR: mitral regurgitation; LBBB: left bundle branch block; ACE-I: angiotensin-converting-enzyme inhibitor; ARB: angiotensin receptor blocker OR: odds ratio; 95% CI: 95% confidence interval.
